Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OpGen, Inc.    OPGN


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

OPGEN INC : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)

03/30/2020 | 04:19pm EST

Item 5.07 - Submission of Matters to a Vote of Security Holders.

On March 30, 2020, OpGen, Inc. (the "Company") held a Special Meeting of the Stockholders of the Company. At the Annual Meeting, the total number of shares represented in person or by proxy was 2,897,277 of the 5,582,280 shares of Common Stock outstanding and entitled to vote at the Special Meeting as of the record date, January 24, 2020. The following matters were voted upon at the Special Meeting:

1.                      The vote of the stockholders to approve the business

combination transaction pursuant to an Implementation Agreement dated September 4, 2019, by and among the Company, Curetis N.V., a public company with limited liability under the Laws of the Netherlands, and Crystal GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany and wholly owned subsidiary of the Company, was:

                      2,859,412 votes     FOR the resolution
                      15,938 votes        AGAINST the resolution
                      21,927 votes        ABSTAIN

2.                      The vote of the stockholders to approve the issuance or

reservation for issuance of 2,662,564 shares of the Common Stock to be issued or reserved for issuance in connection with the transaction contemplated by the Implementation Agreement in accordance with the Implementation Agreement and as required by and in accordance with the applicable rules of The Nasdaq Capital Market, was:

                      2,757,765 votes     FOR the resolution
                      108,223 votes       AGAINST the resolution
                      31,289 votes        ABSTAIN

3.                      The vote of the stockholders to approve a proposal to

adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Special Meeting, the Company is not authorized to consummate the transactions contemplated by Proposals No. One and Two, was:

                      2,761,736 votes     FOR the resolution
                      94,385 votes        AGAINST the resolution
                      41,156 votes        ABSTAIN

Item 8.01 - Other Events.

On March 30, 2020, the Company issued a press release announcing the results of the Special Meeting of Stockholders held in connection with the business combination transaction with Curetis GmbH. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

© Edgar Online, source Glimpses

All news about OPGEN, INC.
11/24OPGEN INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equ..
11/24OPGEN : Announces $10 Million Private Placement Priced at the Market
11/24OpGen, Inc. Announces $10 Million Private Placement Priced at the Market
11/16OPGEN : Note 2 - Liquidity and management's plans
11/13OPGEN : Corporate Presentation (PDF)
11/13OPGEN INC : Entry into a Material Definitive Agreement, Other Events, Financial ..
11/12OPGEN : Ares Genetics Commercially Launches NGS-based Antibiotic Resistance Test..
11/12OpGen Group Company Ares Genetics Commercially Launches NGS-based Antibiotic ..
11/12OPGEN INC : Results of Operations and Financial Condition, Financial Statements ..
11/11OPGEN : Reports Third Quarter 2020 Financial Results and Provides Business Updat..
More news
Financials (USD)
Sales 2020 4,12 M - -
Net income 2020 -24,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,16x
Yield 2020 -
Capitalization 39,5 M 39,5 M -
Capi. / Sales 2020 9,58x
Capi. / Sales 2021 3,53x
Nbr of Employees 39
Free-Float 99,9%
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 3
Average target price 5,33 $
Last Close Price 1,96 $
Spread / Highest target 188%
Spread / Average Target 172%
Spread / Lowest Target 155%
EPS Revisions
Oliver Schacht Chief Executive Officer & Director
Bill E. Rhodes Non-Executive Chairman
Johannes Bacher Chief Operating Officer
Timothy C. Dec CFO, Secretary & Chief Accounting Officer
Vadim Sapiro Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
OPGEN, INC.73.45%40
LONZA GROUP AG56.17%44 950
MODERNA, INC.403.89%39 001
CELLTRION, INC.82.32%36 284
SEAGEN INC.44.08%29 684